

ASX release

30 November 2017

ATCOR APPOINTS CRAIG COOPER AS CEO

AtCor Medical Holdings Limited (ASX: ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, today announced the appointment of Craig Cooper as Chief Executive Officer and Executive Director with effect from December 1st, 2017.

As part of a renewed strategic direction for the company, initially Mr. Cooper will focus on:

- Strengthening AtCor as the leader in hypertension management;
- Expanding the company's products into new health professional markets and geographies;
- Leveraging AtCor's existing patents and technologies into new devices and products including wearables for both the clinical and consumer markets; and
- Identifying new opportunities in health and med-tech for the company to expand in both hypertension management and other high growth health and med-tech segments.

Mr Cooper has founded multiple successful health, digital media, technology, and wellness businesses – and was also the co-founder of the telecommunications company Boost Mobile USA. He is recognised as a global expert and thought leader in mobile and wireless technology as well as digital health and med-tech-related businesses. His venture capital funds have raised over A\$1 billion in capital and have funded some of the most significant global digital media, health and technology companies. Prior to relocating to Los Angeles, Mr Cooper was also the co-founder of NRG Asia-Pacific, the largest independent power producer in Australia with over A\$5 billion in energy assets.

Donal O'Dwyer, Non-Executive Chairman, said "The board is excited that Craig has accepted the role of CEO of AtCor. His experience of establishing and building successful businesses, combined with his strong contacts in the health technology and digital sectors, will enable us to take advantage of the many opportunities for AtCor's SphygmoCor® technology. His appointment, we believe, is a new beginning for the company."

Craig Cooper commented "I am delighted to be leading AtCor through this next phase of growth. The current business operations provide significant upside, especially taking into account new guidelines for hypertension management in the USA which are focusing health professionals on the need for more preventative care. I'm also looking forward to identifying new opportunities in health and med-tech - one of the fastest growing market segments, expected to be over A\$7 trillion by 2020."

Mr Cooper holds dual honours degrees in law and economics from the University of Sydney He plans to divide his time between Sydney and Los Angeles, California.

Basic terms of Mr Cooper's employment agreement are:

- Annual salary of US\$300,000.
- A share package is to be offered, subject to shareholder approval, for 6 million shares for no consideration. Shares will be allotted as follows:
 - 2 million shares once 30 day volume weighted average share price (VWAP) exceeds \$0.05;
 - 2 million shares once 30 day VWAP exceeds \$0.08; and
 - 2 million shares once 30 day VWAP exceeds \$0.12.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to non-invasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension diagnosis and management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Donal O'Dwyer – Chairman
+61 (2) 9874 8761

Peter Manley –CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au